Cadrenal Therapeutics holds annual stockholder meeting

• Cadrenal Therapeutics held its annual shareholder meeting on Sept. 24, 2026.
• Shareholders backed an amendment to the 2022 Successor Equity Incentive Plan, lifting the share pool by 323,542 to 1,000,000.
• The plan change reflects shareholder authorization only; it does not confirm any awards have been granted.
• Stockholders ratified WithumSmith+Brown as independent registered public accounting firm for the year ending Dec. 31, 2026.
• Approval was also granted to issue up to 960,000 common shares upon exercise of Series C-1 warrants; issuance depends on exercises.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cadrenal Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-104647), on September 29, 2026, and is solely responsible for the information contained therein.